Premium
The effects of MK‐185 on thyroid function
Author(s) -
Ryan Jerome R.,
Jain Adesh,
Maha George E.,
McMahon F. Gilbert
Publication year - 1971
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt1971123464
Subject(s) - dose , medicine , placebo , endocrinology , thyroid function , thyroxine binding proteins , thyroid , iodine , globulin , chemistry , hormone , blood proteins , thyroid function tests , alternative medicine , organic chemistry , pathology
MK‐185, (2‐acetoamidoethyl [4‐chlorophenyl] [3‐trifluoromethyl phenoxy] acetate) produced a significant reduction in serum protein‐bound iodine and an increase in triiodothyroxine resin uptake in 11 patients with types III and IV hyperlipoproteinemia. The drug was administered orally at dosages of 10, 15, and 20 mg. per kilogram per day each for a period of 4 weeks, respectively. There were 4 week pre‐ and posttreatment periods with placebo. The free thyroxine levels and 131 1 24 hour thyroidal uptake before and after MK‐185 therapy did not show significant change. Although thyroid‐binding globulin capacity was reduced, the change was not significant. It is proposed that the drug interferes with the binding of thyroxine by plasma proteins.